These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 20070039)

  • 21. Use of pattern recognition analysis to identify underlying relationships of Doxorubicin derivatives optimized for breast cancer treatment.
    Bartzatt R
    ISRN Oncol; 2011; 2011():585192. PubMed ID: 22091424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a simple carrier molecule to enhance drug penetration of dermal layers by utilizing multivariate methods, structure property correlations, and continuous system modeling.
    Bartzatt R
    Physiol Chem Phys Med NMR; 2004; 36(1):37-53. PubMed ID: 15789972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
    Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTP carcinogenesis studies of 2,2-bis(bromomethyl)-1,3-propanediol, nitromethane, and 1,2,3-trichloropropane (cas nos. 3296-90-0, 75-52-5, and 96-18-4) in guppies (Poecilia reticulata) and medaka (Oryzias latipes) (Waterborne Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2005 Oct; (528):1-190. PubMed ID: 16362062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.
    Chlebowski RT; Brzechwa-Adjukiewicz A; Cowden A; Block JB; Tong M; Chan KK
    Cancer Treat Rep; 1984 Mar; 68(3):487-91. PubMed ID: 6322986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pattern recognition methods investigation of ellipticines structure-activity relationships.
    de Melo LC; Braga SF; Barone PM
    J Mol Graph Model; 2007 Mar; 25(6):912-20. PubMed ID: 17049892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of anticancer agents utilizing streptozocin for in silico optimization of properties and pattern recognition identification of group features.
    Bartzatt R
    Open Med Chem J; 2008 Sep; 2():81-6. PubMed ID: 19662148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pirarubicin (THP-adriamycin)].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2819-27. PubMed ID: 3046496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative molecular field analysis of cytotoxic beta-carboline analogs.
    Hou XR; Chen Q; Cao RH; Peng WL; Xu AL
    Acta Pharmacol Sin; 2004 Jul; 25(7):959-65. PubMed ID: 15210072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensely potent doxorubicin analogues: structure-activity relationship.
    Farquhar D; Cherif A; Bakina E; Nelson JA
    J Med Chem; 1998 Mar; 41(6):965-72. PubMed ID: 9526570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, antitumor evaluation, molecular modeling and quantitative structure-activity relationship (QSAR) of some novel arylazopyrazolodiazine and triazine analogs.
    El-Shafei A; Fadda AA; Khalil AM; Ameen TA; Badria FA
    Bioorg Med Chem; 2009 Jul; 17(14):5096-105. PubMed ID: 19527933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
    Liang JF; Yang VC
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intrapleural administration of pirarubicin in the treatment of malignant pleural effusion].
    Gotoh T; Nakamura T; Hiramori N; Fujii T; Fujita Y; Kida T; Arimoto T; Sakai M; Iwasaki Y; Tanaka Y
    Gan To Kagaku Ryoho; 1991 Sep; 18(12):2121-7. PubMed ID: 1653558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
    Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
    Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines.
    Wang J; Chan JY; Fong CC; Tzang CH; Fung KP; Yang M
    Liver Int; 2009 Oct; 29(9):1338-47. PubMed ID: 19627484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma.
    Kurokawa Y; Matoba R; Nagano H; Sakon M; Takemasa I; Nakamori S; Dono K; Umeshita K; Ueno N; Ishii S; Kato K; Monden M
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6029-38. PubMed ID: 15447987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV).
    Homma H; Mezawa S; Doi T; Miyanishi K; Takada K; Kukitsu T; Oku T; Masuko E; Nojiri S; Niitsu Y
    Hepatogastroenterology; 2004; 51(58):1135-9. PubMed ID: 15239261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
    Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
    Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.